Acelyrin To Take Tepezza Competitor Into Phase III In TED
Investors Seem Unconvinced
With new Phase I/II data for its anti-IGF-1 agent lonigutamab, Acelyrin will move into Phase III in thyroid eye disease. But how competitive it will be versus Tepezza or Viridian’s Phase III candidate is uncertain.
